Boyu Capital is a private equity firm that invests in consumer, retail, media and technology, healthcare, and financial services sectors.
Business Model: B2C
Revenue: $5M
Employees: 11-50
Address: 88 Queensway
City: Hong Kong
State: other
Zip:
Country: HK
Boyu Capital Consultancy Co. Ltd is a private equity firm specializing in investments in China. Boyu Capital Consultancy Co. Ltd was founded on September 28, 2010 and is based in Hong Kong with an additional office in Beijing, China.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2018 | KLOOK | Series D | 200M |
11/2018 | NetEase Cloud Music | Series B | 600M |
7/2020 | Antengene Corporation | Series C | 97M |
12/2019 | Kuaishou Technology | Series F | 3B |
7/2016 | CStone Pharmaceuticals | Series A | 150M |
12/2021 | Recurrent.ai | Venture Round | 38M |
8/2021 | MediTrust Health | Series C | 308.3M |
7/2018 | Trax | Series D | 0 |
2/2018 | Viela Bio | Series A | 0 |
11/2021 | Vision Medicals | Series D | 47M |
2/2017 | iQiyi | Series G | 1.5B |
8/2021 | Zeekr | Series A | 500M |
11/2021 | J&a;T Express | Private Equity Round | 0 |
8/2020 | Yuanfudao | Series G | 1.2B |
7/2018 | MEGVII | Series D | - |
7/2018 | Curon Biopharma | Series A | 150M |
9/2018 | LianLian Pay | Venture Round | 146.6M |
9/2021 | XSKY Data Technology | Series E | 0 |
1/2021 | KLOOK | Series E | 0 |
8/2021 | Pulse Medical Technology | Series C | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
6/2021 | RecBio | Series C | 156.3M |
9/2017 | LifeMine Therapeutics | Series A | 0 |
5/2018 | China Chengxin Credit | Series A | 0 |
9/2019 | Chengjia Apartment | Series A | 300M |
12/2020 | SciNeuro | Series A | 100M |
11/2017 | Berry Oncology | Series A | 121.2M |
4/2021 | J&a;T Express | Private Equity Round | 2B |
5/2013 | Berry Genomics | Series B | 14.7M |
8/2021 | MediTrust Health | Series C | 0 |
5/2018 | Brii Biosciences | Venture Round | 260M |
10/2021 | WT Microtech Medical | Series E | 153M |
5/2018 | CStone Pharmaceuticals | Series B | 260M |
1/2019 | Yimidida | Series D | 266.1M |
3/2020 | Yuanfudao | Series G | 1B |
3/2020 | Pinduoduo | Post-IPO Equity | 1.1B |
6/2019 | Waterdrop | Series C | 144.6M |
4/2021 | Adcentrx Therapeutics | Series A | 50M |
9/2022 | Animoca Brands | Convertible Note | 110M |
9/2012 | Alibaba Group | Private Equity Round | 0 |
3/2020 | Yatsen Holding | Series D | 240M |
11/2021 | Positive Sequence Biology | Series A | 0 |
6/2022 | Frontera Therapeutics | Series B | 0 |
11/2021 | Edge Medical Robotics | Series C | 0 |
1/2021 | 4Paradigm | Series D | 0 |
1/2019 | Antengene Corporation | Series B | 0 |
1/2021 | Lalamove | Series F | 1.5B |
6/2014 | COFCO | Post-IPO Equity | - |
2/2014 | LY.com | Series C | 82.3M |
8/2021 | Abogen Biosciences | Series C | 0 |
6/2021 | ArriVent Biopharma | Series A | 81M |
2/2022 | ArriVent Biopharma | Series A | 69M |
12/2022 | ArriVent Biopharma | Series B | 0 |
11/2020 | D3 Bio | Series A | 200M |
12/2021 | Jinke | Post-IPO Equity | 478.6M |
6/2022 | Evat Master | Series A | 0 |
6/2022 | Frontera Therapeutics | Series B | 0 |
6/2022 | Evat Master | Series A | 0 |
5/2022 | Shuaike Pet Food Products | Private Equity Round | 0 |
3/2022 | MoreSec | Series D | 0 |
2/2022 | ArriVent Biopharma | Series A | 0 |
12/2021 | Recurrent.ai | Venture Round | 0 |
12/2021 | Jinke | Post-IPO Equity | 0 |
11/2021 | Vision Medicals | Series D | 0 |
11/2021 | J&a;T Express | Private Equity Round | 0 |
11/2021 | Positive Sequence Biology | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|